MedTrace Logo

Efficacy and Safety of Ivermectin Against Dengue Infection

NCT02045069 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2015-11-02

No results posted yet for this study

Summary

This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection.

Conditions

  • Dengue Fever

Interventions

DRUG

2 days Ivermectin

200-400 µg/kg once daily for 2 days and placebo once daily at D3

DRUG

3 days Ivermectin

200 -400 µg/kg once daily for 3 days

DRUG

Placebo

Placebo once daily for 3 days

Sponsors & Collaborators

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • Mahidol University

    lead OTHER

Principal Investigators

  • Panisadee Avirutnan, MD, PhD. · Division of Dengue Hemorrhagic Fever Research Department of Research and Development, Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok 10700, THAILAND

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-02-29
Completion
2016-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045069 on ClinicalTrials.gov